Journal
INTERNATIONAL IMMUNOLOGY
Volume 28, Issue 8, Pages 411-419Publisher
OXFORD UNIV PRESS
DOI: 10.1093/intimm/dxw019
Keywords
cancer; immunotherapy; mutation; neoantigen
Categories
Funding
- Pershing Square Sohn Cancer Alliance
- STARR Cancer Consortium
- Frederick Adler Chair
- Stand Up to Cancer
Ask authors/readers for more resources
Immune checkpoint blockade has demonstrated substantial promise for the treatment of several advanced malignancies. These agents activate the immune system to attack tumor cells. For example, agents targeting CTLA4 and programmed cell death 1 (PD-1) have resulted in impressive response rates and, in some cases, durable remissions. Neoantigens are mutations that encode immunologically active proteins that can cause the immune system to recognize the affected cell as foreign. Recent data have made it clear that these mutations are, in large part, the functional targets of immune checkpoint blockade. This review summarizes the key discoveries leading up to this important conclusion and discusses possible applications of neoantigens in cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available